Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation

Lucas N. Marzec, Jingyan Wang, Nilay D Shah, Paul S. Chan, Henry H. Ting, Kensey L. Gosch, Jonathan C. Hsu, Thomas M. Maddox

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Background Oral anticoagulation (OAC) with warfarin is underused for atrial fibrillation (AF). The availability of direct oral anticoagulants (DOACs) may improve overall OAC rates in AF patients, but a large-scale evaluation of their effects has not been conducted. Objectives This study assessed the effect of DOAC availability on overall OAC rates for nonvalvular AF. Methods Between April 1, 2008 and September 30, 2014, we identified 655,000 patients with nonvalvular AF and a CHA2DS2-VASc score of >1 in the National Cardiovascular Data Registry PINNACLE registry. Temporal trends in overall OAC and individual warfarin and DOAC use were analyzed. Multivariable hierarchical logistic regression identified patient factors associated with OAC and DOAC use. Practice variation of OAC and DOAC use was also assessed. Results Overall OAC rates increased from 52.4% to 60.7% among eligible AF patients (p for trend <0.01). Warfarin use decreased from 52.4% to 34.8% (p for trend <0.01), and DOAC use increased from 0% to 25.8% (p for trend <0.01). An increasing CHA2DS2-VASc score was associated with higher OAC use (odds ratio [OR]: 1.06; 95% confidence interval [CI]: 1.05 to 1.07), but with lower DOAC use (OR: 0.97; 95% CI: 0.96 to 0.98). Significant practice variation was present in OAC use (median odds ratio [MOR]: 1.52; 95% CI: 1.45 to 1.57) and in DOAC use (MOR: 3.58; 95% CI: 3.05 to 4.13). Conclusions Introduction of DOACs in routine practice was associated with improved rates of overall OAC use for AF, but significant gaps remain. In addition, there is significant practice-level variation in OAC and DOAC use.

Original languageEnglish (US)
Pages (from-to)2475-2484
Number of pages10
JournalJournal of the American College of Cardiology
Volume69
Issue number20
DOIs
StatePublished - May 23 2017

Fingerprint

Anticoagulants
Atrial Fibrillation
Odds Ratio
Confidence Intervals
Warfarin
Registries
Logistic Models

Keywords

  • atrial fibrillation
  • direct oral anticoagulants
  • oral anticoagulation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation. / Marzec, Lucas N.; Wang, Jingyan; Shah, Nilay D; Chan, Paul S.; Ting, Henry H.; Gosch, Kensey L.; Hsu, Jonathan C.; Maddox, Thomas M.

In: Journal of the American College of Cardiology, Vol. 69, No. 20, 23.05.2017, p. 2475-2484.

Research output: Contribution to journalArticle

Marzec, Lucas N. ; Wang, Jingyan ; Shah, Nilay D ; Chan, Paul S. ; Ting, Henry H. ; Gosch, Kensey L. ; Hsu, Jonathan C. ; Maddox, Thomas M. / Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation. In: Journal of the American College of Cardiology. 2017 ; Vol. 69, No. 20. pp. 2475-2484.
@article{7795beac38064e5081b16216b8b47a09,
title = "Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation",
abstract = "Background Oral anticoagulation (OAC) with warfarin is underused for atrial fibrillation (AF). The availability of direct oral anticoagulants (DOACs) may improve overall OAC rates in AF patients, but a large-scale evaluation of their effects has not been conducted. Objectives This study assessed the effect of DOAC availability on overall OAC rates for nonvalvular AF. Methods Between April 1, 2008 and September 30, 2014, we identified 655,000 patients with nonvalvular AF and a CHA2DS2-VASc score of >1 in the National Cardiovascular Data Registry PINNACLE registry. Temporal trends in overall OAC and individual warfarin and DOAC use were analyzed. Multivariable hierarchical logistic regression identified patient factors associated with OAC and DOAC use. Practice variation of OAC and DOAC use was also assessed. Results Overall OAC rates increased from 52.4{\%} to 60.7{\%} among eligible AF patients (p for trend <0.01). Warfarin use decreased from 52.4{\%} to 34.8{\%} (p for trend <0.01), and DOAC use increased from 0{\%} to 25.8{\%} (p for trend <0.01). An increasing CHA2DS2-VASc score was associated with higher OAC use (odds ratio [OR]: 1.06; 95{\%} confidence interval [CI]: 1.05 to 1.07), but with lower DOAC use (OR: 0.97; 95{\%} CI: 0.96 to 0.98). Significant practice variation was present in OAC use (median odds ratio [MOR]: 1.52; 95{\%} CI: 1.45 to 1.57) and in DOAC use (MOR: 3.58; 95{\%} CI: 3.05 to 4.13). Conclusions Introduction of DOACs in routine practice was associated with improved rates of overall OAC use for AF, but significant gaps remain. In addition, there is significant practice-level variation in OAC and DOAC use.",
keywords = "atrial fibrillation, direct oral anticoagulants, oral anticoagulation",
author = "Marzec, {Lucas N.} and Jingyan Wang and Shah, {Nilay D} and Chan, {Paul S.} and Ting, {Henry H.} and Gosch, {Kensey L.} and Hsu, {Jonathan C.} and Maddox, {Thomas M.}",
year = "2017",
month = "5",
day = "23",
doi = "10.1016/j.jacc.2017.03.540",
language = "English (US)",
volume = "69",
pages = "2475--2484",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "20",

}

TY - JOUR

T1 - Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation

AU - Marzec, Lucas N.

AU - Wang, Jingyan

AU - Shah, Nilay D

AU - Chan, Paul S.

AU - Ting, Henry H.

AU - Gosch, Kensey L.

AU - Hsu, Jonathan C.

AU - Maddox, Thomas M.

PY - 2017/5/23

Y1 - 2017/5/23

N2 - Background Oral anticoagulation (OAC) with warfarin is underused for atrial fibrillation (AF). The availability of direct oral anticoagulants (DOACs) may improve overall OAC rates in AF patients, but a large-scale evaluation of their effects has not been conducted. Objectives This study assessed the effect of DOAC availability on overall OAC rates for nonvalvular AF. Methods Between April 1, 2008 and September 30, 2014, we identified 655,000 patients with nonvalvular AF and a CHA2DS2-VASc score of >1 in the National Cardiovascular Data Registry PINNACLE registry. Temporal trends in overall OAC and individual warfarin and DOAC use were analyzed. Multivariable hierarchical logistic regression identified patient factors associated with OAC and DOAC use. Practice variation of OAC and DOAC use was also assessed. Results Overall OAC rates increased from 52.4% to 60.7% among eligible AF patients (p for trend <0.01). Warfarin use decreased from 52.4% to 34.8% (p for trend <0.01), and DOAC use increased from 0% to 25.8% (p for trend <0.01). An increasing CHA2DS2-VASc score was associated with higher OAC use (odds ratio [OR]: 1.06; 95% confidence interval [CI]: 1.05 to 1.07), but with lower DOAC use (OR: 0.97; 95% CI: 0.96 to 0.98). Significant practice variation was present in OAC use (median odds ratio [MOR]: 1.52; 95% CI: 1.45 to 1.57) and in DOAC use (MOR: 3.58; 95% CI: 3.05 to 4.13). Conclusions Introduction of DOACs in routine practice was associated with improved rates of overall OAC use for AF, but significant gaps remain. In addition, there is significant practice-level variation in OAC and DOAC use.

AB - Background Oral anticoagulation (OAC) with warfarin is underused for atrial fibrillation (AF). The availability of direct oral anticoagulants (DOACs) may improve overall OAC rates in AF patients, but a large-scale evaluation of their effects has not been conducted. Objectives This study assessed the effect of DOAC availability on overall OAC rates for nonvalvular AF. Methods Between April 1, 2008 and September 30, 2014, we identified 655,000 patients with nonvalvular AF and a CHA2DS2-VASc score of >1 in the National Cardiovascular Data Registry PINNACLE registry. Temporal trends in overall OAC and individual warfarin and DOAC use were analyzed. Multivariable hierarchical logistic regression identified patient factors associated with OAC and DOAC use. Practice variation of OAC and DOAC use was also assessed. Results Overall OAC rates increased from 52.4% to 60.7% among eligible AF patients (p for trend <0.01). Warfarin use decreased from 52.4% to 34.8% (p for trend <0.01), and DOAC use increased from 0% to 25.8% (p for trend <0.01). An increasing CHA2DS2-VASc score was associated with higher OAC use (odds ratio [OR]: 1.06; 95% confidence interval [CI]: 1.05 to 1.07), but with lower DOAC use (OR: 0.97; 95% CI: 0.96 to 0.98). Significant practice variation was present in OAC use (median odds ratio [MOR]: 1.52; 95% CI: 1.45 to 1.57) and in DOAC use (MOR: 3.58; 95% CI: 3.05 to 4.13). Conclusions Introduction of DOACs in routine practice was associated with improved rates of overall OAC use for AF, but significant gaps remain. In addition, there is significant practice-level variation in OAC and DOAC use.

KW - atrial fibrillation

KW - direct oral anticoagulants

KW - oral anticoagulation

UR - http://www.scopus.com/inward/record.url?scp=85019205382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019205382&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2017.03.540

DO - 10.1016/j.jacc.2017.03.540

M3 - Article

VL - 69

SP - 2475

EP - 2484

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 20

ER -